Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Mikael L. Rinne"'
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 11, Pp 1653-1665 (2023)
Abstract Sabatolimab is a novel immunotherapy with immuno‐myeloid activity that targets T‐cell immunoglobulin domain and mucin domain‐3 (TIM‐3) on immune cells and leukemic blasts. It is being evaluated for the treatment of myeloid malignanci
Externí odkaz:
https://doaj.org/article/b3c448f399bf45c38812f5dfd2cc1e41
Autor:
Yaara Zwang, Oliver Jonas, Casandra Chen, Mikael L Rinne, John G Doench, Federica Piccioni, Li Tan, Hai-Tsang Huang, Jinhua Wang, Young Jin Ham, Joyce O'Connell, Patrick Bhola, Mihir Doshi, Matthew Whitman, Michael Cima, Anthony Letai, David E Root, Robert S Langer, Nathanael Gray, William C Hahn
Publikováno v:
eLife, Vol 6 (2017)
Activating mutations involving the PI3K pathway occur frequently in human cancers. However, PI3K inhibitors primarily induce cell cycle arrest, leaving a significant reservoir of tumor cells that may acquire or exhibit resistance. We searched for gen
Externí odkaz:
https://doaj.org/article/e53a69f812244f4b946e1569b458a6f8
Autor:
Meghan Cifrino, Lakshmi Nayak, Jennifer Stefanik, Wenya Linda Bi, Christine McCluskey, Thomas Graillon, Ian F. Dunn, Patrick Y. Wen, David A. Reardon, Deborah LaFrankie, Keith L. Ligon, Alona Muzikansky, Joseph Driver, Ugonma Chukwueke, David Meredith, Andrew D. Cherniack, Rameen Beroukhim, Ricardo McFaline-Figueroa, Ossama Al-Mefty, Christina Taubert, Sandro Santagata, Samantha E Hoffman, Lisa Doherty, Mikael L. Rinne, Raymond Y. Huang, Sarah C. Gaffey, E. Antonio Chiocca, Yvonne Y. Li, Eudocia Q. Lee, Ziming Du
Publikováno v:
Neuro-Oncology. 24:101-113
Background Programmed death ligand 1 (PD-L1) contributes to tumor immunosuppression and is upregulated in aggressive meningiomas. We performed a phase II study of nivolumab, a programmed death 1 (PD-1) blocking antibody among patients with grade ≥2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e5b61609555c87e43ca6dd9087c056b2
https://doi.org/10.1093/neuonc/noab118
https://doi.org/10.1093/neuonc/noab118
Autor:
Sun Loo, Rupa Narayan, Mikael L. Rinne, Mika Kontro, Andrew M. Stein, Oliver G. Ottmann, Haiying Sun, Norbert Vey, Jeroen Janssen, Guillermo Garcia-Manero, Steve Knapper, Kimmo Porkka, Sebastian Scholl, Jordi Esteve, Fariba Khanshan, Andrew H. Wei, Elie Traer, Uma Borate, Purushotham Naidu, Natalia Tovar, Martin Wermke, Anisa Mohammed, Na Zhang, Andrew M. Brunner, Siyan Xu, Serena Liao
Publikováno v:
Blood. 136:40-42
Background: Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor expressed on multiple immune cells and on leukemic stem/progenitor cells and blasts, but not on normal hematopoietic stem ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6bb09ee8bf5bdd44fad153ba28a376b8
https://doi.org/10.1182/blood-2020-137307
https://doi.org/10.1182/blood-2020-137307
Autor:
Jennifer Bruno, L. Burt Nabors, Shyam K. Tanguturi, Howard Colman, Mary Welch, Brittany Fisher-Longden, William Pisano, Eudocia Q. Lee, Mehdi Touat, Tracy T. Batchelor, Geffrey Fell, Jan Drappatz, Emily Lapinskas, Rifaquat Rahman, David A. Reardon, Manmeet Ahluwalia, Wenya Linda Bi, Isabel Arrillaga-Romany, Ugonma Chukwueke, Thomas Kaley, Jaroslaw T. Hepel, David Schiff, Christine McCluskey, Heinrich Elinzano, Lakshmi Nayak, E. Antonio Chiocca, Evanthia Galanis, Christine Lu-Emerson, Daphne A. Haas-Kogan, Brian M. Alexander, David Meredith, J Ricardo McFaline-Figueroa, Lorenzo Trippa, Mikael L. Rinne, Daniel N. Cagney, Rameen Beroukhim, Maria Lavallee, Ayal A. Aizer, Keith L. Ligon, Omar Arnaout, Lisa Doherty, Sarah Gaffey, Andrew B. Lassman, Shanna Dowling, Patrick Y. Wen
Publikováno v:
Neuro Oncol
BACKGROUND The Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) is a phase II platform trial with Bayesian adaptive randomization and deep genomic profiling to more efficiently test experimental agents in newly diagnosed gl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::171f08c798e14a7556a16f997d2c8248
https://doi.org/10.1093/neuonc/noab196.265
https://doi.org/10.1093/neuonc/noab196.265
Autor:
Andrew M. Brunner, Uma Borate, Andrew H. Wei, Mikael L. Rinne, Rupa Narayan, Purushotham Naidu, Oliver G. Ottmann, Steve Knapper, Siyan Xu, Anisa Mohammed, Martin Wermke, Andrew Lewandowski, Sun Loo, Mika Kontro, Elie Traer, Natalia Tovar, Andrew M. Stein, Na Zhang, Haiying Sun, Kimmo Porkka, Norbert Vey, Guillermo Garcia-Manero, Sebastian Scholl, Jeroen Janssen
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S349-S350
Context: Sabatolimab is an investigational immuno-myeloid therapy targeting TIM-3. The STIMULUS clinical trial program has been designed to evaluate sabatolimab in multiple phase 1–3 trials in patients with MDS and AML. Here, we report PK and clini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b1e7f76f08241dfc7f3af6fafad233f
https://doi.org/10.1016/s2152-2650(21)01810-3
https://doi.org/10.1016/s2152-2650(21)01810-3
Autor:
Lorenzo Trippa, David Meredith, E. Antonio Chiocca, Mehdi Touat, Lakshmi Nayak, Mary Welch, David Schiff, Jack Geduldig, Omar Arnaout, Louis B. Nabors, Christine McCluskey, Rameen Beroukhim, Thomas Kaley, Mikael L. Rinne, Sandro Santagata, Howard Colman, Shyam K. Tanguturi, Manmeet Ahluwalia, Brian M. Alexander, Rifaquat Rahman, Daniel N. Cagney, Andrew B. Lassman, David A. Reardon, Patrick Y. Wen, Maria Lavallee, Geoffrey Fell, Ugonma Chukwueke, Heinrich Elinzano, Ayal A. Aizer, Keith L. Ligon, Jose Mcfaline-Figueroa, Fiona Watkinson, Isabel Arrillaga-Romany, Jaroslaw T. Hepel, Daphne A. Haas-Kogan, Lisa Doherty, Christine Lu-Emerson, Tracy T. Batchelor, Shanna Dowling, Wenya Linda Bi, Jennifer Brunno, Evanthia Galanis, Brittany Fisher-Longden, Jan Drappatz, Sarah C. Gaffey, Eudocia Q. Lee
Publikováno v:
Neuro Oncol
BACKGROUND CC-115 is an oral, CNS-penetrant, selective inhibitor of mammalian target of rapamycin kinase (mTOR) and deoxyribonucleic acid-dependent protein kinase (DNA-PK). Both targets are important in glioblastoma; PI3K/Akt/mTOR signaling is hypera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1359aba25163584a46b0b39b1b4b697
https://europepmc.org/articles/PMC7650886/
https://europepmc.org/articles/PMC7650886/
Autor:
Anne-Sophie Wavreille, Shumei Qiu, Viviana Cremasco, Glenn Dranoff, Xiaomo Jiang, Melanie Verneret, Mikael L. Rinne, Nidhi Patel, Hongbo Lu, Fiona Sharp, Catherine Anne Sabatos-Peyton, Pushpa Jayaraman, Stephanie Schwartz, Lisa Baker, Tyler Longmire
Publikováno v:
Regular and young investigator award abstracts.
Background TIM-3 is expressed on leukemic stem cells (LSCs) and blasts in AML,1 2 and TIM-3 expression on MDS blasts correlates with disease progression.3 Functional evidence for TIM-3 in AML was established with an anti-TIM-3 antibody which inhibite
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e87dc33fabc033282f628bb055f38512
https://doi.org/10.1136/jitc-2020-sitc2020.0439
https://doi.org/10.1136/jitc-2020-sitc2020.0439
Autor:
Norifumi Ishikawa, Kazutaka Sunami, Shinsuke Iida, Kazuto Natsume, Masafumi Taniwaki, Kiyohiko Hatake, Hironobu Minami, Mikael L. Rinne, Risa Sekiguchi
Publikováno v:
International journal of hematology. 113(6)
PIM447, a pan-proviral integration site for Moloney leukemia (PIM) kinase inhibitor, has shown preclinical activity in multiple myeloma (MM). This phase I, open-label, multicenter, dose-escalation study aimed to determine the maximum tolerated dose (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e7e1e893596a97496fcd5c2de8846fd
https://pubmed.ncbi.nlm.nih.gov/33638035
https://pubmed.ncbi.nlm.nih.gov/33638035
Autor:
Mikael L. Rinne, Patrick Y. Wen, David A. Reardon, Prashin Unadkat, Lais Cabrera, Sylvia Kurz, Lakshmi Nayak, Eudocia Q. Lee, David Hastie, Raymond Y. Huang
Publikováno v:
Neurology. 91:e1355-e1359
ObjectiveTo investigate the question of whether salvage therapy with the programmed cell death protein 1 (PD-1)–blocking antibodies nivolumab or pembrolizumab with or without bevacizumab offers clinical or survival benefit in patients with recurren
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cf6a481d6246840c416c82667eea144
https://doi.org/10.1212/wnl.0000000000006283
https://doi.org/10.1212/wnl.0000000000006283